全文获取类型
收费全文 | 11938篇 |
免费 | 692篇 |
国内免费 | 50篇 |
专业分类
耳鼻咽喉 | 83篇 |
儿科学 | 482篇 |
妇产科学 | 286篇 |
基础医学 | 1781篇 |
口腔科学 | 211篇 |
临床医学 | 1319篇 |
内科学 | 2498篇 |
皮肤病学 | 240篇 |
神经病学 | 1219篇 |
特种医学 | 303篇 |
外科学 | 1132篇 |
综合类 | 76篇 |
一般理论 | 9篇 |
预防医学 | 966篇 |
眼科学 | 213篇 |
药学 | 865篇 |
中国医学 | 51篇 |
肿瘤学 | 946篇 |
出版年
2023年 | 83篇 |
2022年 | 73篇 |
2021年 | 301篇 |
2020年 | 215篇 |
2019年 | 306篇 |
2018年 | 363篇 |
2017年 | 245篇 |
2016年 | 280篇 |
2015年 | 369篇 |
2014年 | 479篇 |
2013年 | 676篇 |
2012年 | 977篇 |
2011年 | 1035篇 |
2010年 | 539篇 |
2009年 | 483篇 |
2008年 | 795篇 |
2007年 | 853篇 |
2006年 | 787篇 |
2005年 | 756篇 |
2004年 | 677篇 |
2003年 | 662篇 |
2002年 | 591篇 |
2001年 | 67篇 |
2000年 | 51篇 |
1999年 | 74篇 |
1998年 | 90篇 |
1997年 | 80篇 |
1996年 | 52篇 |
1995年 | 71篇 |
1994年 | 59篇 |
1993年 | 44篇 |
1992年 | 43篇 |
1991年 | 34篇 |
1990年 | 24篇 |
1989年 | 25篇 |
1988年 | 29篇 |
1987年 | 17篇 |
1986年 | 28篇 |
1985年 | 25篇 |
1984年 | 32篇 |
1983年 | 37篇 |
1982年 | 38篇 |
1981年 | 37篇 |
1980年 | 33篇 |
1979年 | 22篇 |
1978年 | 22篇 |
1977年 | 11篇 |
1976年 | 11篇 |
1975年 | 13篇 |
1972年 | 10篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Alessandro Mandurino-Mirizzi Vilma Kajana Stefano Cornara Alberto Somaschini Andrea Demarchi Marco Galazzi Gabriele Crimi Marco Ferlini Rita Camporotondo Massimiliano Gnecchi Maurizio Ferrario Luigi Oltrona-Visconti Gaetano M. De Ferrari 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2021,31(7):2140-2143
BackgroundContrast associated-acute kidney injury (CA-AKI) has been associated with adverse outcomes after ST-segment elevation myocardial infarction (STEMI). However, early markers of CA-AKI are still needed to improve risk stratification. We investigated the association between elevated serum uric acid (eSUA) and CA-AKI in patients with STEMI treated with primary percutaneous coronary intervention (pPCI).Methods and resultsSerum creatinine (Scr) was measured at admission and 24, 48 and 72 h after pPCI. CA-AKI was defined as an increase of 25% (CA-AKI 25%) or 0.5 mg/dl (CA-AKI 0.5) of Scr level above the baseline after 48 h following contrast administration. Multivariable analyses to investigate CA-AKI predictors were performed by binary logistic regression and multivariable backward logistic regression model.In the 3023 patients considered, CA-AKI was more frequent among patients with eSUA as compared with patients with normal SUA levels, considering both CA-AKI definitions (CA-AKI25%: 20.8% vs 16.2%, p < 0.012; CA-AKI 0.5: 10.1% vs 5.8%, p < 0.001). The association between eSUA and CA-AKI was confirmed at multivariable analyses (CA-AKI 25%: odd ratio 1.32, 95% CI 1.03–1.69, p = 0.027; CA-AKI 0.5: odd ratio 1.76, 95% CI 1.11–2.79, p = 0.016).ConclusionElevated serum uric acid is associated with CA-AKI after reperfusion in patients with STEMI treated with pPCI. 相似文献
3.
Andrea Ferrari MD Daniel Orbach MD Michela Casanova MD Max M. van Noesel MD Pablo Berlanga MD Bernadette Brennan MD Nadege Corradini MD Reineke A. Schoot MD Gema L. Ramirez-Villar MD Lisa Lyngsie Hjalgrim MD Rita Alaggio MD Gabriela Guillen Burrieza MD Akmal Safwat MD Alison L. Cameron MD Rick R. van Rijn MD Veronique Minard-Colin MD Ilaria Zanetti BSc Gianni Bisogno MD Julia C. Chisholm MD Johannes H. M. Merks MD 《Cancer》2023,129(16):2542-2552
Background
Limited data exist on the clinical behavior of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) with distant metastases at onset, and a clear standard of care has not yet been defined.Methods
This cohort study reports on pediatric adult-type metastatic NRSTS enrolled in two concurrent prospective European studies, i.e., the randomized BERNIE study and the single-arm MTS 2008 study developed by the European paediatric Soft tissue sarcoma Study Group. Treatment programs were originally designed for patients with metastatic rhabdomyosarcoma, i.e., nine courses of multidrug chemotherapy (with or without bevacizumab in the BERNIE study), followed by 12 cycles of maintenance therapy, whereas radiotherapy and/or surgery (on primary tumor and/or metastases) were delayed until after seven courses of chemotherapy had been administered.Results
The study included 61 patients <21 years old treated from July 2008 to December 2016. The lung was the site of metastases in 75% of the cases. All patients received multi-agent chemotherapy, 44% had local therapy to primary tumor, and 18% had treatment of metastases. Median time to progression/relapse was 6 months. A high rate of tumor progression was observed during the initial part of the chemotherapy program. With a median follow-up of 41.5 months (range, 2–111 months), 3-year event-free survival and overall survival were 15.4% (95% confidence interval [CI], 7.6–25.7) and 34.9% (95% CI, 22.7–47.5), respectively. There were no statistically significant differences in outcome depending on the type of treatment administered.Conclusions
The study confirmed the overall poor outcome for patients with metastatic NRSTS, whose treatment remains a challenge.Plain Language Summary
- Pediatric non-rhabdomyosarcoma soft tissue sarcomas form a heterogeneous group of rare tumors.
- Although recent international studies have defined the standard of care for patients with localized disease, limited data are available on the clinical behavior of patients with distant metastases.
- This study on 61 metastatic cases treated on two prospective European protocols confirms that the chances of survival of such patients are often dismal and a standard treatment is still lacking.
4.
Maurizio Bifulco Domenico D. De Falco Rita P. Aquino Simona Pisanti 《Journal of Cosmetic Dermatology》2019,18(6):1613-1616
Trotula de Ruggiero is supposed to be one of the first female physician of the history, or at least the first who practiced, taught, and wrote medical texts inside the illustrious medieval Medical School of Salerno around the XI‐XII centuries. Here we retrace the steps of her fascinating history from historical cues to legendary anecdotes, through the analysis of the medical texts which were ascribed to her in the Middle Ages and that were very popular around Europe for several centuries, prevalently dealing with all the aspects of women's medical problems, with a focus on dermatology, cosmetic science, and obstetrics/gynecology. 相似文献
5.
Fiore Manganelli Silvia Parisi Maria Nolano Francesco Miceli Stefano Tozza Chiara Pisciotta Rosa Iodice Vincenzo Provitera Rita Cicatiello Stephan Zuchner Maurizio Taglialatela Tommaso Russo Lucio Santoro 《Journal of the peripheral nervous system : JPNS》2019,24(4):330-339
The development of patient‐specific induced pluripotent stem cells (iPSCs) offered interesting insights in modeling the pathogenesis of Charcot‐Marie‐Tooth (CMT) disease and thus we decided to explore the phenotypes of iPSCs derived from a single CMT patient carrying a mutant ATP1A1 allele (p.Pro600Ala). iPSCs clones generated from CMT and control fibroblasts, were induced to differentiate into neural precursors and then into post‐mitotic neurons. Control iPSCs differentiated into neuronal precursors and then into post‐mitotic neurons within 6‐8 days. On the contrary, the differentiation of CMT iPSCs was clearly defective. Electrophysiological properties confirmed that post‐mitotic neurons were less mature compared to the normal counterpart. The impairment of in vitro differentiation of CMT iPSCs only concerned with the neuronal pathway, because they were able to differentiate into mesendodermal cells and other ectodermal derivatives. ATP1A1 was undetectable in the few neuronal cells derived from CMT iPSCs. ATP1A1 gene mutation (p.Pro600Ala), responsible for a form of axonal CMT disease, is associated in vitro with a dramatic alteration of the differentiation of patient‐derived iPSCs into post‐mitotic neurons. Thus, the defect in neuronal cell development might lead in vivo to a decreased number of mature neurons in ATP1A1‐CMT disease. 相似文献
6.
7.
8.
Catarina Oliveira Catarina Marques Vânia Simões Leina Spencer Rita Poeira Margarida Casteleira 《Brazilian Journal of Anesthesiology》2019,69(2):218-221
Background and objectives
Sugamadex is a modified gamma‐cyclodextrin, the first selective agent for reversal of neuromuscular blockade induced by steroidal non‐depolarizing muscle relaxants, with greater affinity for rocuronium. In this article we present a case of severe bradycardia and asystole following sugammadex administration.Case report
A 54‐year‐old male patient, ASA II, with a history of hypertension, dyslipidemia and obesity, who underwent an emergency umbilical herniorrhaphy under balanced general anesthesia. Intraoperative muscle relaxation was maintained with rocuronium. At the end of the surgery, the patient maintained a neuromuscular block with two TOF responses, and sugammadex (200 mg) was administered. About thirty seconds after its administration, the patient developed marked bradycardia (HR 30 bpm) followed by asystole.Conclusions
Documented bradycardia and asystole were attributed to the administration of sugammadex. This case shows that, although rare, cardiac arrest is a possible adverse effect of this drug, and that the knowledge of this situation can be determinant for the patient's evolution. 相似文献9.
Lucena Rita de Melo-Carneiro Pedro Sampaio Aline Santos de Almeida Nadia Rossi Ponte Ana Marta Vieira de Brito Wanderley Daniele de Mattos Adriana Marques Robatto Ana Paola Argollo Nayara 《Journal of autism and developmental disorders》2022,52(9):4202-4203
Journal of Autism and Developmental Disorders - 相似文献
10.
Vilde D. Haakensen Anand Khadse Vandana Sandhu Ann Rita Halvorsen Steinar K. Solberg Lars H. Jørgensen Odd Terje Brustugun Elin H. Kure Åslaug Helland 《International journal of cancer. Journal international du cancer》2020,147(10):2957-2966
Personalised cancer treatment depends on identification of therapeutically relevant biological subgroups of patients for assessing effect of treatment and to discover new therapeutic options. By analyses in heterogeneous patient populations, the effects may be lost in noise. Squamous cell carcinoma of the lung is a major killer worldwide. Despite recent advances, mortality is high and response to therapies varies greatly from patient to patient. Target search in biologically relevant subgroups may identify treatment options not so far discovered. A total of 198 patients undergoing surgery for squamous cell carcinomas of the lung were included in the study. The tumours were analysed for copy number alterations (n = 152) and gene expression from tumour (n = 188) and normal lung (n = 21), with both data levels present in 140 patients. We studied alterations in tumours harbouring mutations in TP53 and in previously published gene expression subtypes. Genes with consistent alterations in both genomic levels were identified as putative biomarkers. Results were validated in TCGA. The most convincing biomarker in TP53 mutated squamous cell carcinomas of the lung was BIRC5 with amplification in 36% of mutated samples, 5% in wild-type samples and a 17%-fold change of expression between TP53 mutated tumours and normal lung tissue. BIRC5 was significantly altered in the classical and primitive subtypes. We suggest BIRC5 as a putative predictive biomarker and putative druggable target in squamous cell lung carcinomas harbouring TP53 mutation or classified as classical and primitive subtypes. 相似文献